Actavis® Metformin ER was recalled after FDA tests found high levels of a cancer-causing chemical called NDMA.
Actavis Metformin Recall
In June 2020, the FDA announced a recall for Actavis® metformin extended-release (Metformin ER) because the diabetes medication is contaminated with high levels of a cancer-causing chemical impurity.
What Metformin Diabetes Drugs Were Recalled?
The recall was issued by Teva Pharmecauticals USA, Inc., for Actavis® Metformin Extended-Release Tablets (500mg and 750mg) in 100-count and 1000-count bottles.
- Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, white to off-white capsule shaped tablets, debossed with an Andrx logo with “571”on one side and “500” on the opposite side.
- Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, light yellow capsule shaped tablets, debossed with an Andrx logo with “577” on one side and “750” on the opposite side.
List of Cancers Linked to NDMA
The recalled metformin is contaminated with N-Nitrosodimethylamine (NDMA), a substance that is believed to cause cancer in humans. NDMA exposure has been linked to the following types of cancer:
- Liver cancer
- Kidney cancer
- Intestinal cancer
- Stomach cancer
- Pancreatic cancer
- Colon cancer
- Esophageal cancer
- Ovarian cancer
- Testicular cancer
- Bladder cancer
- And more
Metformin Cancer Lawsuits
A growing number of lawsuits have been filed by people who developed cancer after taking medications that were contaminated by NDMA, including heartburn drugs like Zantac® and blood pressure drugs like Valsartan.
These lawsuits accuse drug-makers of failing to test their medications for toxic impurities that could significantly increase a patient’s risk of cancer, especially patients who take a contaminated medication every day for many years.